Doxazosin
Cat.No:ID2940 Solarbio
CAS:74191-85-8
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Endocrinology & Hormones >
DoxazosinCAS:74191-85-8
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Solid
Qty:
Size:
CAS | 74191-85-8 |
Name | Doxazosin |
Molecular Formula | C23H25N5O5 |
Molecular Weight | 451.48 |
Solubility | Soluble in DMSO(Need ultrasonic) |
Purity | ≥98% |
Appearance | Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL | MFCD00800482 |
SMILES | COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC |
InChIKey | RUZYUOTYCVRMRZ-UHFFFAOYSA-N |
InChI | InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26) |
PubChem CID | 3157 |
Target Point | Adrenergic Receptor |
Passage | Endocrinology & Hormones;GPCR & G Protein;Neuronal Signaling |
Background | Doxazosin, a quinazoline derivative, selectively antagonizes the post-synaptic α1-adrenergic receptors. |
Biological Activity | Doxazosin 是一种喹唑啉衍生物,是一种长效的α1-肾上腺素受体抑制剂,被广泛用于治疗良性前列腺增生和高血压。[1-3] |
In Vitro | Both the enantiomers of doxazosin were highly bound to the plasma proteins of rats,dogs and humans [(-)doxazosin: 89.4%-94.3%;(+)doxazosin: 90.9%-95.4%].(-)Doxazosin and(+)doxazosin show stereoselective plasma protein binding with a significant species difference among rats,dogs and humans.[1] Doxazosin,at concentrations of 5-20 mumol/L,increased LDL binding to hepatic cells in a dose-related manner. Also,in low-density lipoproteins(LDL)and in hepatoma(Hep G2 cells),doxazosin produced dose-related decreases in both newly synthesized cholesterol and cholesterol ester. In rabbit fibroblasts that were LDL receptor negative,de novo cholesterol synthesis was markedly reduced by increasing concentrations of doxazosin.[2] |
In Vivo | In 24 patients with pheochromocytoma,urinary and plasma catecholamine levels tended to decrease or remained unchanged during doxazosin therapy. There were no clinically hazardous abnormalities or problems in hematologic and biochemical laboratory data.[3] |
Data Literature Source | [1]. Sun JA,et al. Stereoselective binding of doxazosin enantiomers to plasma proteins from rats,dogs and humans in vitro. Acta Pharmacol Sin. 2013 Dec;34(12):1568-74. [2]. D'Eletto RD,et al. Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol. 1989;13 Suppl 2:S1-4; discussion S4. [3]. Miura Y,et al. Doxazosin: a newly developed,selective alpha 1-inhibitor in the management of patients with pheochromocytoma. Am Heart J. 1988 Dec;116(6 Pt 2):1785-9. |
Unit | Bottle |
Specification | 50mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.